<DOC>
	<DOCNO>NCT02819726</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , parallel group study compare PK , PD , safety , efficacy , tolerability , immunogenicity SAIT101 versus MabThera® versus Rituxan® patient RA . This study take place globally across approximately 70 study center order randomize approximately 282 patient . The study consist Part A baseline PK efficacy analysis , follow Part B Week 24 52 safety follow-up also collect transition data .</brief_summary>
	<brief_title>A Study Compare Pharmacokinetics , Pharmacodynamics , Safety , Efficacy SAIT101 Versus MabThera® Versus Rituxan® Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Severe RA define : Diagnosis RA accord revise ( 1987 ) ACR criterion classification RA least 3 month prior screen visit ( see Appendix 3 ) . And ≥6 swollen joint ≥6 tender/painful joint ( 66/68 joint count system ) . And Creactive protein ( CRP ) ≥1.0 mg/dL ESR ≥28 mm/hour Screening . And positive RF ( ≥20 units/mL ) antiCCP antibody ( ≥10 units/mL ) Screening . 2 . Patients severe RA inadequate response least 3 month ' treatment ( accord approve treatment dosage ) intolerance ( Investigator 's discretion and/or experience intolerable AE toxicity infusion relate reaction , hypersensitivity , anaphylaxis severe toxicity ) antiTNF therapy ( experience severe AE toxicity ) . 3 . Current treatment RA outpatient basis : Receiving MTX 7.5 25mg/week ( oral parenteral ) least 12 week , include last 4 week prior Day 1 stable dose , via route administration , dose , formulation . Patients receive low dose MTX ( &lt; 10 mg/week ) , stable 4 week prior Day 1 , result document evidence intolerance high dos MTX . 1 . Females pregnant , breastfeeding , plan pregnancy Treatment Period 12 month last infusion study drug . 2 . Class IV per Classification Global Functional Status Rheumatoid Arthritis ( per ACR 1991 Revised Criteria ) ( see Appendix 4 ) wheelchair/bedbound . 3 . History current inflammatory joint disease RA ( include limit gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy Lyme disease ) . 4 . History current systemic autoimmune disorder ( include limit systemic lupus erythematosus , inflammatory bowel disease , pulmonary fibrosis , Felty syndrome , scleroderma , inflammatory myopathy , fibromyalgia , juvenile idiopathic arthritis , mixed connective tissue disease , vasculitis overlap syndrome ) , exception secondary Sjögren 's syndrome . 5 . Primary secondary immunodeficiency ( history , currently active ) , include know history human immunodeficiency virus ( HIV ) infection positive test screening . 6 . History opportunistic infection . 7 . History deep space/tissue infection ( e.g. , fasciitis , abscess , osteomyelitis ) infect prosthetic joint . 8 . Active infection kind ( exclude fungal infection nail bed ) major episode infection require hospitalization treatment i.v . antiinfective agent within 4 week prior Screening oral antiinfective agent within 2 week prior Screening use antibiotic therapy three time last six month prior Screening . 9 . Positive serological test hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) hepatitis C serology . Patients negative HBsAg positive HBcAb must hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) level &lt; 20 IU/mL ( 112 copies/mL ) polymerase chain reaction ( PCR ) . These HBV patient must willing undergo monthly PCR HBV DNA test treatment may participate follow consultation hepatitis expert regard monitoring use HBV antiviral therapy , provide agree receive treatment indicate . An HBV retest perform monthly include Day 1 , Weeks 4 , 8 , 12 , 16 , 20 , 24 , 36 , 52 , unscheduled visit require . Patients positive test HBV vaccine may include ( i.e. , antiHBs+ anti HBc ) . Patients positive hepatitis C virus ( HCV ) antibody eligible PCR negative HCV ribonucleic acid ( RNA ) . 10 . Confirmed current active tuberculosis ( TB ) . Patients latent TB determine positive QuantiFERONTB test may enrol patient write confirmation health care provider ( e.g. , Pulmonologist Infection Specialist ) adequate prophylaxis within screen period evidence tuberculosis chest Xray perform within 3 month Day 1 . 11 . Any significant cardiac disease ( e.g. , coronary artery disease unstable angina , coronary heart failure New York Heart Association Class III IV , familial long QT syndrome , uncontrolled cardiac disease ) . 12 . History moderate severe chronic obstructive pulmonary disease ( COPD ) and/or history severe COPD exacerbation ( ) within last 12 month Screening . 13 . Vaccination live attenuate vaccine within 6 week prior first dose study drug plan administration study participation within 4 week follow discontinuation study drug . Treatment IV Gamma Globulin Prosorba® Column within 6 month prior Day 1 . 14 . History severe allergic reaction anaphylactic reaction biological agent history hypersensitivity component study drug include know hypersensitivity allergy murine product . 15 . Hypogammaglobulinemia screening ( IgG &lt; 600 mg/dL ) . 16 . Patients hemoglobin &lt; 8.5 g/dL , ANC &lt; 1,500 cells/μL platelet count &lt; 75,000 cells/μL Screening . If patient finding marginally limit , retesting allow , Investigator 's discretion , within 30 day period Visit 1 Visit 2 . 17 . Serum creatinine &gt; 2.0 mg/dL ( &gt; 176.8 μmol/L ) glomerular filtration rate ( GFR ) ( measure use modify CockgroftGault equation ) &lt; 50 mL/min/1.73m2 . Liver function : Total bilirubin &gt; 2.0 mg/dL ( &gt; 34 μmol/L ) except patient Gilbert 's Syndrome hemolysis . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 × upper limit normal ( ULN ) . Patients total bilirubin &gt; 2.0 mg/dL possibly due Gilbert 's Syndrome direct bilirubin check . If direct bilirubin normal medical history suggestive/positive Gilbert 's Syndrome , patient successfully meet criterion . The AST ALT may repeat within Screening period initial result exceeds limit , less value accept meet criterion . 18 . History cancer within last 5 year prior Screening , treat anticancer chemotherapy , include solid tumor hematologic malignancy carcinoma situ ( except basal cell squamous cell carcinoma skin carcinoma situ cervix uterus excise cure ) . 19 . Major surgical procedure within 4 week prior plan within 24 week Day 1 , exception surgical procedure dental prosthesis . 20 . Previous treatment B cell modulate B cell depletion therapy , , limited rituximab , belimumab , atacicept , tabalumab , ocrelizumab , ofatumumab , obinutuzumab , epratuzumab experimental treatment . 21 . Injectable corticosteroid within 6 week prior Day 1 . 22 . Participation previous clinical study within 4 week Screening received treatment drug receive regulatory approval indication within minimum 5 halflives prior Day 1 . 23 . Patients , base Investigator 's judgment , clinically significant unstable medical surgical condition may preclude safe complete study participation . Conditions may also include cardiovascular , vascular , pulmonary , hepatic , renal , endocrine neurological condition determine medical history , physical examination , laboratory test electrocardiogram ( ECG ) . 24 . Patients , judgment Investigator , likely noncompliant uncooperative study . 25 . History substance abuse ( alcohol drug ) . 26 . History demyelinate disorder ( multiple sclerosis GuillainBarré syndrome ) . 27 . Patients risk PML : Patients immune deficiency transplant patient immunosuppressive medication Patients receive certain kind chemotherapy Patients receive natalizumab ( Tysabri® ) multiple sclerosis Patients psoriasis long term efalizumab ( Raptiva® ) patient acquire immunodeficiency syndrome ( AIDS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>